Enhancing protein productivities in CHO cells through adenosine uptake modulation - Novel insights into cellular growth and productivity regulation.

Autor: Madabhushi SR; Biologics Process Development, Merck & Co., Inc., Rahway, NJ, USA. Electronic address: sri.madabhushi@merck.com., Chakravarty T; Biologics Process Development, Merck & Co., Inc., Rahway, NJ, USA., Kasza T; Biologics Process Development, Merck & Co., Inc., Rahway, NJ, USA., Padellan M; Biologics Process Development, Merck & Co., Inc., Rahway, NJ, USA., Atieh TB; Biologics Process Development, Merck & Co., Inc., Rahway, NJ, USA., Gupta B; Biologics Process Development, Merck & Co., Inc., Rahway, NJ, USA.
Jazyk: angličtina
Zdroj: New biotechnology [N Biotechnol] 2024 Nov 25; Vol. 83, pp. 163-174. Date of Electronic Publication: 2024 Aug 14.
DOI: 10.1016/j.nbt.2024.08.500
Abstrakt: Maximizing production potential of recombinant proteins such as monoclonal antibodies (mAbs) in Chinese Hamster Ovary (CHO) cells is a key enabler of reducing cost of goods of biologics. In this study, we explored various strategies to utilize adenosine mediated effects in biologics manufacturing processes. Results show that supplementation of adenosine increases specific productivity by up to two-fold while also arresting cell growth. Introducing adenosine in intensified perfusion processes in a biphasic manner significantly enhanced overall productivity. Interestingly, adenosine effect was observed to be dependent on the cell growth state. Using specific receptor antagonists and inhibitors, we identified that ENTs (primarily Slc29a1) mediate the uptake of adenosine in CHO cell cultures. Transcriptomics data showed an inverse correlation between Slc29a1 expression levels and peak viable cell densities. Data suggests that in fed-batch cultures, adenosine can be produced extracellularly. Blocking Slc29a1 using ENT inhibitors such as DZD and DP alone or in combination with CD73 inhibitor, PSB12379, resulted in a twofold increase in peak viable cell densities as well as productivities in fed batch - a novel strategy that can be applied to biologics manufacturing processes. This is the first study that suggests that adenosine production/accumulation in CHO cell cultures can potentially regulate the transition of CHO cells from exponential to stationary phase. We also demonstrate strategies to leverage this regulatory mechanism to maximize the productivity potential of biologics manufacturing processes.
Competing Interests: Declaration of Competing Interest The authors declare that there are no conflicts of interests.
(Copyright © 2024 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: